Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

54.37 -1.72 (-3.07%)
Official Closing Price Updated: 7:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Urged to Join Class Action - Contact Levi &amp; Korsinsky to Learn More
Via TheNewswire.com
Topics Fraud Lawsuit
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Novo Nordisk Pops 8% On 'Significant' Weight Loss For Oral Wegovy
Novo Nordisk stock surged Thursday after its oral version of Wegovy helped patients lose a "significant" amount of weight. 
Via Investor's Business Daily
Eli Lilly Says Its Obesity Pill Topped Novo Nordisk’s Oral Drug In Late-Stage Diabetes Trial
Via Stocktwits
US FDA Alleges Novo Nordisk’s Video On Weight-loss Drugs Featuring Oprah Winfrey Is ‘False Or Misleading’
Via Stocktwits
Novo Nordisk Says New Obesity Treatment Achieved 11.8% Body Weight Reduction In Late-stage Study
Via Stocktwits
Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study
Novo Nordisk's Wegovy cut cardiovascular risks more than tirzepatide in real-world data from patients with obesity and heart disease. 
Via Benzinga
Why Is Everyone Talking About Novo Nordisk Stock?
Competition in various directions is affecting the company's fastest-growing product. 
Via The Motley Fool
'Offices Need To Start Feeling A Little Bit More Like Hotels,' Behind One CBRE Exec's Approach To The Future Of In-Person Work
 
Via Benzinga
Dow Futures Surge After Fed Signals Possibility Of More Rate Cuts This Year: META, PLTR, PYPL, GOOGL Among Stocks To Watch
Via Stocktwits
Topics Economy Stocks
Novo Nordisk Stock Jumps After-Hours On Wegovy Pill Breakthrough As Weight-Loss War With Eli Lilly Heats Up
The Danish drugmaker has already filed the once-daily pill with U.S. regulators, aiming for the first FDA-approved oral GLP-1 treatment for obesity. 
Via Stocktwits
Why Novo Nordisk Stock Popped Today
Novo Nordisk lost half its value over the past year. Is it cheap enough to buy now? 
Via The Motley Fool
Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors - Contact Levi & Korsinsky
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors - Contact Levi &amp; Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
2 High-Yield Dividend Stocks You'll Wish You Had Bought 10 Years From Now
These dividend payers cranked up their payouts over the past decade, and they could do it again. 
Via The Motley Fool
Why Novo Nordisk Stock Popped Today
The Wegovy maker reported positive results from a clinical trial of a next-generation obesity treatment. 
Via The Motley Fool
Novo Nordisk Navigates a GLP-1 Gold Rush: Soaring Obesity Drug Sales Clash with Revised Outlook Amidst Mounting Competition
Copenhagen, Denmark – Pharmaceutical giant Novo Nordisk (NYSE: NVO) has reported a robust second quarter for 2025, with impressive revenue and net income figures largely propelled by the formidable... 
Via MarketMinute
Topics Earnings Economy Intellectual Property
Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy
FDA warns Hims & Hers that its semaglutide products are misbranded due to misleading claims and asks for corrective steps within 15 days. 
Via Benzinga
Stock Of The Day: Is The Novo Nordisk Death Spiral Finally Over?
Novo Nordisk has been in a downtrend for more than a year. But a reversal may be underway, and a rally may follow. 
Via Benzinga
Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment
Novo Nordisk plans to seek FDA approval for a high-dose Wegovy, matching Eli Lilly's Zepbound with another weight-loss option for patients. 
Via Benzinga
3 Undervalued Healthcare Stocks to Buy Now While They're Cheap
In an otherwise hot stock market, healthcare stocks are underperforming. 
Via The Motley Fool
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Novo Nordisk A/S Sued for Securities Law Violations - Investors Should Contact Levi &amp; Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Here Is My Top Stock Pick Among the Weight Loss Industry Leaders
The weight loss drug market may reach $95 billion within five years. 
Via The Motley Fool
What's Going On With Novo Nordisk Shares Monday?
Novo Nordisk shares are trading higher Monday after the company announced European Union approval for oral semaglutide to reduce cardiovascular death, heart attack and stroke. 
Via Benzinga
Novo Nordisk's Rybelsus Now First Oral GLP-1 RA In Europe With Proven Heart Health Impact
EMA approved Rybelsus' label update after the SOUL trial showed it cuts heart attack, stroke, and death by 14% in high-risk type 2 diabetes patients. 
Via Benzinga
Novo Nordisk's Weight-Loss Wonders Drive Q2 Growth Amidst Shifting Sands of Competition
Novo Nordisk (NYSE: NVO) has once again demonstrated formidable strength in its obesity care segment, with powerhouse drugs Wegovy and Ozempic propelling the company to a robust Q2 2025 performance.... 
Via MarketMinute
Topics Economy Intellectual Property
Novo Nordisk Faces Headwinds: Competitive Pressures and Compounded Drugs Force Lowered Outlook
Copenhagen, Denmark – Novo Nordisk (NASDAQ: NVO), the pharmaceutical powerhouse synonymous with diabetes and obesity care, has significantly pared back its full-year sales and profit projections for... 
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
Why Novo Nordisk Stock Popped Today
A price cut could help get Novo Nordisk stock back in the race against Eli Lilly. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.